US Section 301 Tariffs: Indian Exporters at Risk

US Section 301 Tariffs Threaten Indian Export Stocks The United States Trade Representative has launched a Section 301 investigation that could place a 12.5% tariff on a range of Indian exports. The trigger is forced labour import restrictions. If this proposal advances, Indian companies with heavy US revenue dependence face real margin compression. This isn't background noise. Section 301 investigations have teeth, and the US-China trade war tariffs after 2018 reshaped global supply chains in ways that took years to unwind. Markets haven't fully priced this in yet. That's either preparation time or a trap for the complacent. Indian export-oriented sectors like textiles, specialty chemicals, and pharmaceuticals sit directly in the crosshairs. The review is ongoing, which means uncertainty is the dominant variable right now. Uncertainty, as any seasoned investor knows, is not friendly to PE multiples. So which stocks are actually exposed? US revenue concentration is what matters, and that number varies dramatically across the affected names. Pharma and Chemicals: Where the Earnings Risk is Sharpest Indian pharmaceutical companies generate a disproportionate share of revenue from the US generics market. [Sun Pharmaceutical Industries](/stock/SUNPHARMA) (NSE: SUNPHARMA) reported approximately 32% of FY24 consolidated revenue from North America, around ₹13,500 crore. A sustained 12.5% tariff doesn't automatically translate to a 12.5% revenue hit. It depends on price elasticity, contract structures, and whether US buyers absorb any of the cost. But the direction of pressure is clear. [Aurobindo Pharma](/stock/AUROPHARMA) (NSE: AUROPHARMA) has even higher US generics exposure, with North America contributing close to 50% of total revenue in recent quarters. That's significant earnings vulnerability. Thin operating margins in generics leave very little room to absorb cost increases before they flow directly into profit cuts. [Divi's Laboratories](/stock/DIVISLAB) (N...